Clareo Health | A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with RRMS according to 2017 revised McDonald criteria
Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment
Patient with a MRI performed within three months before the enrollment
Patient eligible to ozanimod according to SmPC
You may not be if
Patients with clinical forms of MS other than RRMS
Patients unable to participate for various reasons
Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective
